Clinical Trial: Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07048262) titled 'Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)' on June 24.

Brief Summary: This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (nebulized immunoglobulin G [IgG]) compared with placebo over 6 to 12 months to prolong the time to first (TTF) exacerbation as a primary endpoint.

The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 act...